The COVID-19 pandemic will affect every aspect of cancer care and cancer research.
This page is no longer maintained. For The Cancer Letter’s full coverage of COVID-19, click here. Below is a list of meetings that were canceled at the beginning of the pandemic, last updated March 19, 2020, 1:12 P.M. EST Meeting cancellations, postponements, changes: An up-to-date list of oncology conferences
This story is part of The Cancer Letter's ongoing coverage of COVID-19's impact on oncology. A full list of our coverage, as well as the latest meeting cancellations, is available here.As COVID-19 has now officially been declared a source of the pandemic, with increasing incidence across the nation, it is without question that the needs of patients with particular vulnerabilities should garner particular attention.
To get a sense of how COVID-19 will affect oncology in the U.S., The Cancer Letter called Giuseppe Curigliano, associate professor of Medical Oncology at University of Milano and the head of the Division of Early Drug Development at European Institute of Oncology, Italy, who is based in the Lombardy region—the epicenter of the outbreak.
In 1989, I joined Cancer and Leukemia Group B and was introduced into the clinical trials world and a mighty force for good, Dr. Clara D. Bloomfield.
Moffitt execs were made aware of Howard McLeod’s China activities, ousted researcher’s attorney says
Howard McLeod, one of the six researchers ousted at Moffitt Cancer Center under allegations of undisclosed conflicts of interest stemming from their work in China, is publicly disputing his former employer's characterization of his involvement with academic institutions there.
Forecasts of the inevitable spread of coronavirus can be difficult to ignore, especially at a time when many of us are making travel plans for this spring’s big cancer meetings.
Last year, FDA approved 11 new drugs and biologics as well as 30 supplemental indications and four biosimilars, according to commentary by FDA officials published in Nature Reviews.
The FDA Oncologic Drugs Advisory Committee Feb. 26 voted down a vascular-targeted photodynamic therapy for early-stage, low-risk prostate cancer and, in a narrow vote, recommended approval for a combination of a VEGF receptor 2 antagonist and an EGFR-targeting tyrosine kinase inhibitor for front-line treatment of EGFR-positive non-small cell lung cancer.
We were recently presented with the new report from American Cancer Society1 showing the biggest annual decrease in cancer mortality, which was mainly due to decline in smoking, as well as improvements in early detection and treatment.
